166 related articles for article (PubMed ID: 38462041)
1. Novel pharmacological targets for GABAergic dysfunction in ADHD.
Ferranti AS; Luessen DJ; Niswender CM
Neuropharmacology; 2024 May; 249():109897. PubMed ID: 38462041
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism.
Naaijen J; Bralten J; Poelmans G; ; Glennon JC; Franke B; Buitelaar JK
Transl Psychiatry; 2017 Jan; 7(1):e999. PubMed ID: 28072412
[TBL] [Abstract][Full Text] [Related]
3. Reduced Glx and GABA Inductions in the Anterior Cingulate Cortex and Caudate Nucleus Are Related to Impaired Control of Attention in Attention-Deficit/Hyperactivity Disorder.
Mamiya PC; Richards TL; Edden RAE; Lee AKC; Stein MA; Kuhl PK
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563067
[TBL] [Abstract][Full Text] [Related]
4. Aberrant regulation of synchronous network activity by the attention-deficit/hyperactivity disorder-associated human dopamine D4 receptor variant D4.7 in the prefrontal cortex.
Zhong P; Liu W; Yan Z
J Physiol; 2016 Jan; 594(1):135-47. PubMed ID: 26541360
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Dopamine D1-like Receptor Pathways of GABAergic Interneurons in the Anterior Cingulate Cortex of Spontaneously Hypertensive Rats.
Satoh H; Suzuki H; Saitow F
Neuroscience; 2018 Dec; 394():267-285. PubMed ID: 30394321
[TBL] [Abstract][Full Text] [Related]
6. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction.
Arnsten AF
CNS Drugs; 2009; 23 Suppl 1():33-41. PubMed ID: 19621976
[TBL] [Abstract][Full Text] [Related]
7. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis.
Swanson JM; Kinsbourne M; Nigg J; Lanphear B; Stefanatos GA; Volkow N; Taylor E; Casey BJ; Castellanos FX; Wadhwa PD
Neuropsychol Rev; 2007 Mar; 17(1):39-59. PubMed ID: 17318414
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: Evidence for dopamine transporter dysregulation.
Mortimer N; Ganster T; O'Leary A; Popp S; Freudenberg F; Reif A; Soler Artigas M; Ribasés M; Ramos-Quiroga JA; Lesch KP; Rivero O
Neuropharmacology; 2019 Sep; 156():107557. PubMed ID: 30849401
[TBL] [Abstract][Full Text] [Related]
9. Hyperactivity and impulsivity in adult attention-deficit/hyperactivity disorder is related to glutamatergic dysfunction in the anterior cingulate cortex.
Bauer J; Werner A; Kohl W; Kugel H; Shushakova A; Pedersen A; Ohrmann P
World J Biol Psychiatry; 2018 Oct; 19(7):538-546. PubMed ID: 27973969
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients.
Solleveld MM; Schrantee A; Puts NAJ; Reneman L; Lucassen PJ
Neuroimage Clin; 2017; 15():812-818. PubMed ID: 28725548
[TBL] [Abstract][Full Text] [Related]
11. Impulsivity and Aggression in Female BPD and ADHD Patients: Association with ACC Glutamate and GABA Concentrations.
Ende G; Cackowski S; Van Eijk J; Sack M; Demirakca T; Kleindienst N; Bohus M; Sobanski E; Krause-Utz A; Schmahl C
Neuropsychopharmacology; 2016 Jan; 41(2):410-8. PubMed ID: 26040503
[TBL] [Abstract][Full Text] [Related]
12. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.
Brikell I; Wimberley T; Albiñana C; Pedersen EM; Vilhjálmsson BJ; Agerbo E; Demontis D; Børglum AD; Schork AJ; LaBianca S; Werge T; Mors O; Hougaard DM; Thapar A; Mortensen PB; Dalsgaard S
Am J Psychiatry; 2021 Sep; 178(9):854-864. PubMed ID: 34154395
[TBL] [Abstract][Full Text] [Related]
13. Association of dopaminergic/GABAergic genes with attention deficit hyperactivity disorder in children.
Wang GX; Ma YH; Wang SF; Ren GF; Guo H
Mol Med Rep; 2012 Nov; 6(5):1093-8. PubMed ID: 22895683
[TBL] [Abstract][Full Text] [Related]
14. Mice with reduced glutamate transporter GLT1 expression exhibit behaviors related to attention-deficit/hyperactivity disorder.
Hiraoka Y; Sugiyama K; Nagaoka D; Tsutsui-Kimura I; Tanaka KF; Tanaka K
Biochem Biophys Res Commun; 2021 Aug; 567():161-165. PubMed ID: 34166912
[TBL] [Abstract][Full Text] [Related]
15. The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder.
Sergeant J
Neurosci Biobehav Rev; 2000 Jan; 24(1):7-12. PubMed ID: 10654654
[TBL] [Abstract][Full Text] [Related]
16. Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
Denney CB
J Clin Child Psychol; 2001 Mar; 30(1):98-109. PubMed ID: 11294083
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of tumor suppressor NDRG2 leads to attention deficit and hyperactive behavior.
Li Y; Yin A; Sun X; Zhang M; Zhang J; Wang P; Xie R; Li W; Fan Z; Zhu Y; Wang H; Dong H; Wu S; Xiong L
J Clin Invest; 2017 Dec; 127(12):4270-4284. PubMed ID: 29058689
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
Genro JP; Kieling C; Rohde LA; Hutz MH
Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
[TBL] [Abstract][Full Text] [Related]
19. [Neurobiology of attention deficit/hyperactivity disorder].
Purper-Ouakil D; Lepagnol-Bestel AM; Grosbellet E; Gorwood P; Simonneau M
Med Sci (Paris); 2010 May; 26(5):487-96. PubMed ID: 20510147
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.
Roman T; Rohde LA; Hutz MH
Am J Pharmacogenomics; 2004; 4(2):83-92. PubMed ID: 15059031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
